ATTR Amyloidosis Treatment Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
ATTR Amyloidosis Treatment Market is segmented By Type (Hereditary ATTR Amyloidosis, Wild-type ATTR Amyloidosis), By Treatment (Pharmacological Therapies, Organ Transplantation, Supportive Care), By Route of Administration(Oral, Intravenous, Subcutaneous), By End User (Hospitals, Specialty Clinics, Homecare Settings), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Competitive overview of ATTR Amyloidosis Treatment Market
The major players operating in the ATTR Amyloidosis Treatment Market include Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, Inc., Akcea Therapeutics, Inc., Prothena Corporation plc, Corino Therapeutics, Inc., and AstraZeneca plc.
ATTR Amyloidosis Treatment Market Leaders
- Pfizer Inc.
- Alnylam Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Eidos Therapeutics, Inc.
- Akcea Therapeutics, Inc.
ATTR Amyloidosis Treatment Market - Competitive Rivalry, 2023
ATTR Amyloidosis Treatment Market
(Dominated by major players)
(Highly competitive with lots of players.)